 |
 |
Thank you. Very interesting. Moneesha 2008/7/11 [log in to unmask] <[log in to unmask]>: > A very interesting analysis of the Spheramine trial halt from the Michael J > Fox Foundation - > July 10, 2008 > NEWS IN CONTEXT: Titan Pharmaceuticals Halts Phase 2 Trial of Spheramine > Following Disappointing Results > "In the first week of July 2008, Titan Pharmaceuticals, Inc., announced > that it would halt the Phase 2 trial of its symptomatic Parkinson's therapy > Spheramine. The announcement came in the wake of results showing that the > experimental drug had failed to meet clinical endpoints outlined for the > trial. Only one week earlier, the company had reported positive five-year > data from its Phase 1 open-label trial of the same treatment. > > The Michael J. Fox Foundation spoke with David Standaert, MD, PhD, a member > of the Executive Scientific Advisory Board of The Michael J. Fox Foundation, > to gain a clearer understanding of the seemingly conflicting results, and > what people with PD should take away from the news. Dr. Standaert is the > John and Juanelle Strain Professor of Neurology and Director, Center for > Neurodegeneration and Experimental Therapeutics, at the University of > Alabama at Birmingham...." > see > http://www.michaeljfox.org/newsEvents_parkinsonsInTheNews_article.cfm?ID=369 > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn